Amgen's MariTide stands alone after obesity cull while analysts seek more M&A
Amgen discontinued an early-stage obesity candidate, leaving MariTide as its lead obesity asset while analysts push for more M&A.
Amgen
Amgen is one of the world's largest independent biotechnology companies, developing medicines in oncology, cardiovascular disease, inflammation, bone health, neuroscience, and rare disease. Amgen's portfolio includes biologics like Repatha, Prolia/Xgeva, Otezla, Enbrel (ex-North America), Aranesp, Neulasta, and the recent Horizon Therapeutics acquisition adding Tepezza, Krystexxa, and Ubrelvy.
Company Info
Sector:Biologics / Large-molecule biotechnology
Headquarters:Thousand Oaks, California, USA
Founded:1980
Website:www.amgen.com
Recent News
Amgen doesn't think Repatha's sales wins will stop anytime soon
Amgen sees continued momentum for its cholesterol drug Repatha, expecting the cardiology product's sales growth to keep rolling.
Amgen says hackers stole patient data in cloud breach
Amgen reports hackers stole company and patient information in a data breach, noticing unauthorized activity affecting data stored on cloud platforms hosted by third-party providers in July.
Amgen shares new analysis with FDA in bid to keep Tavneos on the market
Amgen has submitted new analyses to the FDA in a bid to retain marketing authorization for Tavneos (avacopan) following agency concerns about the rare-disease drug's real-world performance.
Amgen sheds around 40 staffers as struggles mount
Amgen has cut approximately 40 positions as the company faces pipeline setbacks and competitive pressure on key products including Tavneos.
Amgen submits analyses to FDA in bid for Tavneos hearing
Amgen has submitted a data package to FDA in a bid to secure a hearing over the agency's recent rejection of Tavneos for a label expansion.
Investors, Amgen agree to resolve tax bill lawsuit for $74M
Amgen agreed to pay $74 million to resolve an investor lawsuit over a $107 billion tax bill.
NICE aims to cut funding for Amgen lung cancer drug Lumykras
NICE aims to cut funding for Amgen lung cancer drug Lumykras Lumykras, which is known as Lumakras in some markets, will no longer be covered by the Cancer Drugs Fund, according to the health technology assessment (HTA) agency. Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in England and Wales, saying the decision does not reflect experience with the lung cancer therapy since it was first made available four years ago.
Amgen recalls almost 1 million bottles of heart failure drug over quality issue
Amgen recalls almost 1 million bottles of heart failure drug over quality issue (reported by BioSpace)
Court halts Colorado price cap on Amgen's blockbuster Enbrel
Court halts Colorado price cap on Amgen's blockbuster Enbrel — Endpoints News coverage of biopharma industry developments.
NEJM retracts pivotal data for Amgen's Tavneos
NEJM retracts pivotal data for Amgen's Tavneos — Endpoints News coverage of biopharma industry developments.
Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns
Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns.
Viridian may have edge over Amgen in eye drug showdown, analysts argue
Viridian may have edge over Amgen in eye drug showdown, analysts argue. (BioPharma Dive.)
An Important Update Regarding TAVNEOS (avacopan)
An Important Update Regarding TAVNEOS (avacopan).
Leadership Team
TBD
CEO
Careers & Job Openings